Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $212.0 million.

  • Arrowhead Pharmaceuticals' Change in Receivables rose 838184.0% to $212.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $266.5 million, marking a year-over-year increase of 1056052.0%. This contributed to the annual value of $57.0 million for FY2025, which is N/A changed from last year.
  • Arrowhead Pharmaceuticals' Change in Receivables amounted to $212.0 million in Q4 2025, which was up 838184.0% from $47.1 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Change in Receivables high stood at $212.0 million for Q4 2025, and its period low was -$68.2 million during Q2 2023.
  • For the 5-year period, Arrowhead Pharmaceuticals' Change in Receivables averaged around $16.3 million, with its median value being $1.2 million (2022).
  • Its Change in Receivables has fluctuated over the past 5 years, first crashed by 996000.0% in 2021, then skyrocketed by 838184.0% in 2025.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Change in Receivables stood at -$10.1 million in 2021, then soared by 477.61% to $38.2 million in 2022, then tumbled by 103.27% to -$1.2 million in 2023, then soared by 300.64% to $2.5 million in 2024, then skyrocketed by 8381.84% to $212.0 million in 2025.
  • Its Change in Receivables was $212.0 million in Q4 2025, compared to $47.1 million in Q3 2025 and $7.5 million in Q2 2025.